Delving into the Latest Updates on AL28979 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

AL28979

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Non-Small Cell Lung CancerSmall Cell Lung Cancer

Inactive Indication-

Originator Organization

Advenchen Laboratories Nanjing Ltd.

Active Organization

Advenchen Laboratories Nanjing Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：研究非小细胞肺癌及其它实体瘤患者单次和多次给予AL28979后的耐受性和安全性。次要目的：初步获得AL28979片治疗非小细胞肺癌及其它实体瘤患者的药代动力学参数。初步评价AL28979片治疗非小细胞肺癌及其它实体瘤患者的有效性。

[Translation]

Primary objective: To investigate the tolerability and safety of single and multiple administrations of AL28979 in patients with non-small cell lung cancer and other solid tumors. Secondary objective: To obtain preliminary pharmacokinetic parameters of AL28979 tablets in the treatment of patients with non-small cell lung cancer and other solid tumors. To preliminarily evaluate the efficacy of AL28979 tablets in the treatment of patients with non-small cell lung cancer and other solid tumors.

Start Date-

Sponsor / Collaborator

Advenchen Laboratories Nanjing Ltd.

100 Clinical Results associated with AL28979

Login to view more data

100 Translational Medicine associated with AL28979

Login to view more data

100 Patents (Medical) associated with AL28979

Login to view more data

100 Deals associated with AL28979

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 1	China	Advenchen Laboratories Nanjing Ltd.	13 May 2026
Small Cell Lung Cancer	Phase 1	China	Advenchen Laboratories Nanjing Ltd.	13 May 2026